Lise Lund Kjems
Plus aucun poste en cours
Fortune : 21 828 $ au 31/05/2024
Profil
Lise Lund Kjems served as the Vice President & Head-Clinical Development at Albireo Pharma, Inc. He then worked as the Chief Medical Officer at Cyclo Therapeutics, Inc. Dr. Kjems holds a doctorate degree from the University of Copenhagen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CYCLO THERAPEUTICS INC
0,06% | 07/03/2023 | 17 053 ( 0,06% ) | 21 828 $ | 31/05/2024 |
Anciens postes connus de Lise Lund Kjems
| Sociétés | Poste | Fin |
|---|---|---|
| CYCLO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/04/2023 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - |
Formation de Lise Lund Kjems
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CYCLO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
